Dianthus Therapeutics | MGTA

Stock Price
26.50
Daily Change
1.84 7.46%
Monthly
29.97%
Yearly
-0.45%
Q3 Forecast
26.28

Peers Price Chg Day Year Date
Celltrion 169,000.00 -1,200.00 -0.71% -11.61% Sep/05
Cspc Pharmaceutical 11.19 0.36 3.32% 140.13% Sep/05
Sino Biopharmaceutical 8.91 0.52 6.20% 183.76% Sep/05
Avita Medical 1.34 0.01 0.75% -48.46% Sep/05
Zhangzhou Pientzehuang Pharmaceutical 203.87 0.94 0.46% 0.69% Sep/05
Kangmei Pharma 2.03 0 0% 15.34% Sep/05
Adcock Ingram Holdings 7,187.00 -13.00 -0.18% 10.77% Sep/05
Tectonic Therapeutic 16.80 -0.47 -2.72% -8.50% Sep/05
Divis Laboratories Ltd 6,009.00 -124.50 -2.03% 16.96% Sep/05
Knight Therapeutics 6.44 0 0% 14.18% Sep/05
IQVIA Holdings 187.68 3.60 1.96% -22.83% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Malin Corporation 8.00 0 0% 29.03% Sep/01
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Medical Developments International 0.58 -0.01 -0.86% 36.90% Sep/05
Neuren Pharmaceuticals 20.48 0.50 2.50% 51.03% Sep/05
Organigram Holdings 2.28 0.08 3.64% -4.20% Sep/05
Organon & Co 10.38 0.70 7.23% -49.40% Sep/05
Pharma Mar 88.40 -2.80 -3.07% 116.88% Sep/05
Revvity 86.64 0.94 1.10% -24.90% Sep/05
Qiagen NV 40.39 0.18 0.44% -1.38% Sep/06
Laboratorios Farma 59.65 -0.10 -0.17% -26.18% Sep/05
Sartorius 193.20 4.90 2.60% -23.42% Sep/06
Tilray 1.64 0.06 3.80% -25.45% Sep/05
Viatris 10.50 0.17 1.65% -6.87% Sep/05
Xeris Pharmaceuticals 7.85 -0.04 -0.51% 212.75% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05


Dianthus Therapeutics Inc traded at $26.50 this Friday September 5th, increasing $1.84 or 7.46 percent since the previous trading session. Looking back, over the last four weeks, Dianthus Therapeutics gained 29.97 percent. Over the last 12 months, its price fell by 0.45 percent. Looking ahead, we forecast Dianthus Therapeutics Inc to be priced at 26.28 by the end of this quarter and at 25.63 in one year, according to Trading Economics global macro models projections and analysts expectations.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.